Loading clinical trials...
Loading clinical trials...
A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/MK-8628 in Haematological Malignancies
Conditions
Interventions
OTX015/Birabresib
Start Date
December 14, 2012
Primary Completion Date
January 20, 2017
Completion Date
January 20, 2017
Last Updated
January 26, 2021
NCT05139017
NCT06285890
NCT06220162
NCT05376111
NCT04065399
NCT04628026
Lead Sponsor
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions